Rank: 107 | Score: 77/100 | Category: Translational | Disease: Alzheimer's Disease
Sequential therapy selection guided by biomarker profiles will achieve superior clinical outcomes compared to fixed sequences in AD treatment.
Addresses the "Therapy Sequencing for Disease-Modifying Combinations in Neurodegeneration" gap — specifically, how biomarker-guided selection of therapy sequences can optimize outcomes.
Alzheimer's disease involves multiple pathological mechanisms including amyloid-beta plaques, tau tangles, neuroinflammation, synaptic loss, and mitochondrial dysfunction. Fixed sequential approaches (e.g., always start with anti-amyloid, then add tau-targeting) fail to account for individual patient heterogeneity.
- Biomarker profiles vary significantly between patients
- Some patients may benefit more from anti-inflammatory therapy first if neuroinflammation dominates
- Others may have minimal amyloid burden but significant tau pathology requiring different sequencing
- Personalized sequencing could improve response rates from ~27% to >50%
Type: Prospective cohort with biomarker stratification
Population:
- Early AD (MCI due to AD or mild AD dementia)
- Age 55-85
- Confirmed amyloid PET positivity or CSF evidence
- Able to undergo all biomarker assessments
| Biomarker |
Purpose |
Timing |
| Amyloid PET (Centiloid) |
amyloid burden |
Baseline + 6mo |
| CSF p-tau217 |
tau pathology |
Baseline + 6mo |
| CSF NfL |
neuroaxonal injury |
Baseline + 6mo + 12mo |
| Neuroinflammation PET (TSPO) |
microglial activation |
Baseline + 6mo |
| FDG-PET |
metabolic dysfunction |
Baseline + 12mo |
| Plasma p-tau217 |
scalable tau tracking |
Q6mo |
Arm A (Standard Sequential):
- Anti-amyloid antibody (lecanemab) → Month 0-6
- Add anti-tau antibody → Month 6-12
- Add neuroprotective agent → Month 12-18
Arm B (Biomarker-Guided Sequential):
- Month 0: Biomarker tier determines first therapy
- High amyloid (>50 Centiloid), moderate tau: Anti-amyloid first
- High neuroinflammation (TSPO SUVR >1.5), moderate amyloid: Anti-inflammatory first
- High tau, low amyloid: Tau-targeted first
- Month 6: Re-biomarker and adjust sequence
- Month 12: Add third agent per biomarker
Arm C (Combination from Start):
- All three mechanisms from Month 0
- Lower doses of each to assess tolerability
n=450 (150 per arm)
- Power: 80% to detect 25% improvement in CDR-SB slope
- Alpha: 0.05 (two-sided)
- Accounting for 20% attrition
24 months primary endpoint
- Interim analyses at 6, 12, 18 months
- Extended follow-up to 36 months
- iPSC-derived neurons from patient subgroups
- Organoid models with different pathology ratios
- Drug response profiling in 2D cultures
- Digital twin for individual patient trajectories
- Bayesian network for therapy selection
- Simulation of 10,000 virtual patients
- CDR-SB change from baseline at 24 months
- Comparison across arms
- Biomarker trajectories: Changes in each biomarker tier
- Response rates: Proportion achieving clinical responder status
- Time to milestone: Time to CDR progression
- Brain volume: Hippocampal atrophy rate
- Biomarker-guided sequencing improves CDR-SB by 0.8-1.5 points vs standard
- Reduces non-responder rate from ~73% to ~50%
- Identifies biomarker profiles predictive of response to each sequence
- All biomarkers clinically available
- anti-amyloid and anti-tau antibodies in clinical use
- Statistical methods established
| Component |
Cost |
| Biomarker assessments |
$3,200/patient |
| Drug costs |
$2,500/patient |
| Clinical coordination |
$1,800/patient |
| Imaging |
$2,000/patient |
| Total |
$9,500/patient |
| Project total |
$4.3M |
- Preparation: 6 months
- Enrollment: 18 months
- Follow-up: 6 months
- Analysis: 3 months
- Total: 33 months
¶ Risks and Mitigations
| Risk |
Probability |
Impact |
Mitigation |
| Biomarker variability |
Medium |
Medium |
Central lab, standardized assays |
| Drug interactions |
Low |
High |
Safety monitoring, dose adjustment |
| Dropout |
Medium |
Medium |
Incentive structure, flexible visits |
| Endpoint variability |
Medium |
Medium |
Multiple endpoints, ITT analysis |
-
15% serious ARIA in any arm: Pause enrollment, safety review
-
2-fold increased adverse events: Terminate arm
- Funding exhaustion: Priority endpoint analysis early
The biomarker-guided sequencing framework developed here can be adapted for:
- Parkinson's disease (alpha-syn + dopamine + neuroinflammation)
- ALS (SOD1 + TDP-43 + neuroinflammation)
- FTD (tau + TDP-43 + progranulin)
This represents a generalizable precision medicine approach.
- Sims et al., Lecanemab in Early Alzheimer's Disease (2023)
- Van Dyck et al., Lecanemab in Early AD (2023)
- Cavallieri et al., Combination therapy in neurodegeneration (2020)
- Zhang et al., Drug repurposing combinations in neurodegeneration (2023)
- Baker et al., Sequential therapy for neurodegenerative diseases (2022)